Hun Ju

Sep 7, 2023 | ashpublications.org | Pier Luigi |Hun Ju |Hôpital Saint-Louis

Previous studies have shown that immune checkpoint inhibition targeting programmed death 1 (PD-1) is an effective therapeutic option for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who are ineligible for or progress after autologous stem cell transplantation (ASCT), with or without treatment with brentuximab vedotin (BV).1-4 As a result, the National Comprehensive Cancer Network treatment guidelines recommend the use of the anti–PD-1 checkpoint inhibitor...